September 23, 2020 -- Precision Virologics and Bharat Biotech obtained the rights for a new chimp-adenovirus COVID-19 vaccine from Washington University School of Medicine in St. Louis.
Precision Virologics has optioned the rights to offer the intranasal vaccine in the U.S., Europe, and Japan, and Bharat has obtained a license for all other markets.
In mouse studies, a single nasal dose has shown protection against the virus. Based on these findings, the U.S. National Institutes of Health is advancing studies in nonhuman primates, according to the companies.